0.7334
Precedente Chiudi:
$0.7755
Aprire:
$0.7628
Volume 24 ore:
1.71M
Relative Volume:
0.17
Capitalizzazione di mercato:
$71.86M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-9.70%
1M Prestazione:
-2.63%
6M Prestazione:
-85.90%
1 anno Prestazione:
-76.03%
Atyr Pharma Inc Stock (ATYR) Company Profile
Nome
Atyr Pharma Inc
Settore
Industria
Telefono
(858) 731-8389
Indirizzo
10240 SORRENTO VALLEY ROAD, SAN DIEGO
Confronta ATYR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
ATYR
Atyr Pharma Inc
|
0.7334 | 75.99M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Atyr Pharma Inc Stock (ATYR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-16 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-09-15 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-09-15 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-09-15 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-09-15 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-02-18 | Iniziato | Leerink Partners | Outperform |
| 2025-01-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-10-04 | Iniziato | Wells Fargo | Overweight |
| 2024-09-05 | Iniziato | Jefferies | Buy |
| 2023-07-05 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-10-12 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-09-21 | Iniziato | Piper Sandler | Overweight |
| 2021-05-10 | Iniziato | Laidlaw | Buy |
| 2020-08-17 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-03-04 | Iniziato | ROTH Capital | Buy |
| 2020-03-02 | Iniziato | Oppenheimer | Outperform |
| 2018-02-14 | Downgrade | JP Morgan | Neutral → Underweight |
| 2017-09-07 | Iniziato | Piper Jaffray | Overweight |
| 2016-12-13 | Downgrade | JP Morgan | Overweight → Neutral |
| 2015-12-16 | Iniziato | Citigroup | Neutral |
| 2015-06-01 | Iniziato | Citigroup | Buy |
| 2015-06-01 | Iniziato | JP Morgan | Overweight |
Mostra tutto
Atyr Pharma Inc Borsa (ATYR) Ultime notizie
Johnson Fistel Investigates Claims on Behalf of aTyr Pharma, Inc. (ATYR) Shareholders - marketscreener.com
aTyr Pharma, Inc. (NASDAQ:ATYR) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
aTyr Pharma, Inc. (NASDAQ:ATYR) Given Consensus Rating of “Hold” by Brokerages - Defense World
Healthy Upside Potential: Atyr Pharma Inc (ATYR) - Setenews
ATYR Deadline: ATYR Investors with Losses Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit - Morningstar
Investors SueWallSt Over aTyr Pharma, Inc. Stock DropContact Levi & Korsinsky to Join - Louisiana First News
Shareholders that lost money on aTyr Pharma, Inc.(ATYR) - GlobeNewswire
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma - galvnews.com
ATYR DEADLINE ALERT: Hagens Berman Alerts aTyr Pharma - GlobeNewswire
ATYR LAWSUIT ALERT: The Gross Law Firm Notifies aTyr Pharma, Inc - GuruFocus
ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
ATYR LAWSUIT ALERT: The Gross Law Firm Notifies aTyr Pharma, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - marketscreener.com
ATyr Pharma, Inc. Investigated for Securities Fraud ViolationsContact the DJS Law Group to Discuss Your RightsATYR - marketscreener.com
ATYR DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma - TMX Newsfile
ATYR Lawsuit: Hagens Berman Urges aTyr Pharma Investors to Act by Dec. 8 Deadline in Suit Over Trial Failure - GlobeNewswire
ATYR Lawsuit: Hagens Berman Urges aTyr Pharma Investors to Act by Dec. 8 Deadline in Suit Over Trial Failure - GlobeNewswire Inc.
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma - Newsfile
מועד אחרון לתביעה נגד ATYR: רוזן, משרד עורכי דין מוערך בעולם, מעודדים את משקיעי ATyr Pharma, Inc עם הפסדים של מעל מאה אלף דולר, להשיג ייעוץ לפני המועד החשוב של 8 בדצמבר בתביעה ייצוגית בניירות ערך - GlobeNewswire Inc.
ATYR DEADLINE MONDAY: ROSEN, A GLOBALLY RESPECTED LAW FIRM, - GlobeNewswire
aTyr Pharma Receives Nasdaq Deficiency Notice - TipRanks
Investors who lost money on aTyr Pharma, Inc.(ATYR) should contact Levi & Korsinsky about pending Class ActionATYR - Your Wyoming Link
ATyr Pharma Inc. (ATYR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - marketscreener.com
ATYR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
SueWallSt Podcast Series Launches With Focus on aTyr Pharma, Inc. (ATYR) Fraud Allegations - ACCESS Newswire
ATYR 3-DAY DEADLINE ALERT: Hagens Berman Urges aTyr Pharma Inves - GuruFocus
ATYR 3-DAY DEADLINE ALERT: Hagens Berman Urges aTyr Pharma Investors to Act by Dec. 8 Deadline in Suit Over Trial Failure - marketscreener.com
Holzer & Holzer, LLC Reminds Investors of Upcoming December - GlobeNewswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff - GlobeNewswire
Deadline Soon: aTyr Pharma Inc. (ATYR) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit - The AI Journal
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma - WV News
aTyr Pharma, Inc. Sued for Securities Law ViolationsContact The Gross Law Firm Before December 8, 2025 to Discuss Your RightsATYR - PR Newswire
aTyr Pharma, Inc. $ATYR Shares Bought by Geode Capital Management LLC - Defense World
ATYR 5-DAY DEADLINE ALERT: Hagens Berman Urges aTyr Pharma Inves - GuruFocus
ATYR 5-DAY DEADLINE ALERT: Hagens Berman Urges aTyr Pharma Investors to Act by Dec. 8 Deadline in Suit Over Trial Failure - Morningstar
Shareholders SueWallSt in New Class Action Against aTyr Pharma, Inc.Act Now - Nasdaq
ATYR INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma - GlobeNewswire
Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma - MarketScreener
ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
Deadline Alert: aTyr Pharma Inc. (ATYR) Shareholders Who - GlobeNewswire
Shareholders that lost money on aTyr Pharma, Inc.(ATYR) should c - GuruFocus
Portnoy Law Firm Announces Class Action on Behalf of aTyr Pharma, Inc. Investors - GlobeNewswire
The Gross Law Firm Notifies aTyr Pharma, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineATYR - Lelezard
Will aTyr Pharma Inc. (471A) stock profit from fiscal stimulusQuarterly Risk Review & Low Volatility Stock Recommendations - Newser
How aTyr Pharma Inc. (471A) stock valuation compares with sectorMarket Trend Review & Consistent Profit Trading Strategies - Newser
ATYR 1-WEEK DEADLINE ALERT: Hagens Berman Urges aTyr Pharma Investors to Act by Dec. 8 Deadline in Suit Over Trial Failure - Morningstar
UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma - marketscreener.com
Bragar Eagel & Squire, P.C. Urgently Reminds Stockholders - GlobeNewswire
Lost Money on aTyr Pharma, Inc.(ATYR)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky - GlobeNewswire
aTyr Pharma Inc. (ATYR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - Barchart.com
Atyr Pharma Inc Azioni (ATYR) Dati Finanziari
Non sono disponibili dati finanziari per Atyr Pharma Inc (ATYR). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
Atyr Pharma Inc Azioni (ATYR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| SCHIMMEL PAUL | Director |
Oct 09 '25 |
Buy |
0.94 |
317,999 |
299,364 |
1,413,023 |
| Gross Jane A | Director |
Mar 17 '25 |
Buy |
4.00 |
3,750 |
15,000 |
9,750 |
| Broadfoot Jill Marie | Chief Financial Officer |
Feb 04 '25 |
Sale |
3.78 |
1,254 |
4,740 |
31,763 |
| DENYES NANCY | General Counsel |
Feb 04 '25 |
Sale |
3.78 |
899 |
3,398 |
26,555 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):